High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
about
Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.Clinical population pharmacokinetics and toxicodynamics of linezolid.Retrospective analysis of the risk factors for linezolid-induced thrombocytopenia in adult Japanese patients.Risk factors for linezolid-associated thrombocytopenia in adult patients.Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.The association between risk factors and time of onset for thrombocytopenia in Japanese patients receiving linezolid therapy: a retrospective analysis.Linezolid-Associated Thrombocytopenia in Children With Renal Impairment.Safety profiles of old and new antimicrobials for the treatment of MRSA infections.Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients.Mechanism Underlying Linezolid-induced Thrombocytopenia in a Chronic Kidney Failure Mouse Model.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds?Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis.Predictive score of haematological toxicity in patients treated with linezolid.Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infectionsSystematic Therapeutic Drug Monitoring for Linezolid: Variability and Clinical Impact.Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.Risk factors associated with high linezolid trough plasma concentrations.Comment on: Pharmacokinetics of high dosage of linezolid in two morbidly obese patients.Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically-relevant Concentrations in cultured Human HL-60 promyelocytes and THP-1 monocytes.Comparative analysis of lactic acidosis induced by linezolid and vancomycin therapy using cohort and case-control studies of incidence and associated risk factors.Thrombocytopenia with Tedizolid and Linezolid.Effect of coadministration of rifampicin on the pharmacokinetics of linezolid: clinical and animal studies
P2860
Q33410244-31E74500-A30E-4289-B697-7C4FA9541E83Q33413269-AD8985D6-85EA-4B4A-AD8F-192D0328BC4CQ33415838-A896712F-13F7-4383-B884-A11418105668Q33417036-6B6526DD-0D3F-4A6A-85C0-C00B6CA29585Q33417790-9AAE1602-B364-4FB4-96CA-B081A7A7C359Q33420826-C4B5E3A4-2F84-43C0-A178-164DFB5B9819Q33426216-51D2FDB7-D836-4BA3-9709-6F1ED1523FDEQ33429168-6697D0AC-1148-4191-8D92-4D7E04B035C9Q33439246-B2C27894-36BF-43B0-BF25-0941EC98096BQ33440964-03F49785-8430-4FB6-BD59-281E914FBAE7Q34894900-BCF5C3DC-9F4F-4D73-9B3F-13F3615A76BDQ36802059-B85AFD63-435F-4FEB-9F14-31E146045FE3Q38777085-4BFE1887-6BF6-41C4-B66C-8AFC33FAF580Q38786623-7FC6C45F-92FC-4BBC-A04C-A2853AE136B7Q38876028-F8D7DC5D-B8A8-4E0C-895B-DF1B506E96E2Q38929509-D6375732-1628-45CC-B909-EDD2FE41A678Q39067666-7CAF3342-5175-4C89-A979-7642211653FEQ40121784-34736185-C840-4FA7-93D7-E9D71F024B14Q40354366-9F06770B-B68B-4FC2-9F19-3FC94824C407Q40683242-9F236916-1011-458F-839D-5E236AC58061Q44424597-99382902-EFBA-4EA2-B6E2-157130833712Q47269635-59B3DC5F-26B3-406B-9768-7E265FB9FB43Q47339328-092F54E2-E4E1-45B5-BE0F-BA3BE9EFC8E6Q47737103-D2E7AC9C-8A86-4B5C-A84B-FEEA065E2F7BQ59127470-C80F844D-704B-4760-8711-CBC52437A828
P2860
High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
High plasma linezolid concentr ...... olid-induced thrombocytopenia.
@ast
High plasma linezolid concentr ...... olid-induced thrombocytopenia.
@en
type
label
High plasma linezolid concentr ...... olid-induced thrombocytopenia.
@ast
High plasma linezolid concentr ...... olid-induced thrombocytopenia.
@en
prefLabel
High plasma linezolid concentr ...... olid-induced thrombocytopenia.
@ast
High plasma linezolid concentr ...... olid-induced thrombocytopenia.
@en
P2093
P2860
P356
P1476
High plasma linezolid concentr ...... olid-induced thrombocytopenia.
@en
P2093
Akihiro Hisaka
Hiroshi Suzuki
Hiroshi Yotsuyanagi
Koh Okamoto
Kyoji Moriya
Nahoko Yata
Shuji Hatakeyama
Takehito Yamamoto
Yoko Nukui
P2860
P304
P356
10.1093/JAC/DKT133
P407
P577
2013-04-26T00:00:00Z